Section I - IDENTIFICATION

Common/Trade Name: Cyclosporin Concentrate for Injection USP (50mg/ml; 5ml/vial)
Chemical Name: [R-[R*,R*-(E)]]-cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-α-amino-butryrl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl)
Synonyms: Sandimmune® Injection, Antibiotic S7481F1, Ramihyphin A
Manufacturer's Name: BEN VENUE LABORATORIES, INC.
Address: 300 NORTHFIELD ROAD
          BEDFORD, OH 44146
Emergency Telephone Number: Chemtrec: 1(800) 424-9300
Telephone Number for Info.: (440) 232-3320 or (800) 562-4797
Medical Emergency: Professional Services: 1(800) 521-5169
Date Prepared: July 15, 1999
Date Revised: August 29, 2001
Date Revised: March 17, 2003
Date Revised: October 20, 2005
Date Revised: July, 9, 2007

Section II - HAZARDOUS INGREDIENTS/COMPOSITION INFORMATION

<table>
<thead>
<tr>
<th>Component</th>
<th>%</th>
<th>CAS#</th>
<th>OSHA PEL</th>
<th>ACGIH TLV</th>
<th>Recommended</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cyclosporine, USP</td>
<td>5%</td>
<td>79217-60-0</td>
<td>NONE</td>
<td>NONE</td>
<td>0.02mg/m³</td>
</tr>
<tr>
<td>Ethyl Alcohol, USP (v/v)</td>
<td>26.4%</td>
<td>64-17-5</td>
<td>1000 ppm</td>
<td>1000 ppm</td>
<td>NONE</td>
</tr>
<tr>
<td>Cremophor® (polyoxy-Ethylated castor oil)</td>
<td>65%</td>
<td>61791-12-6</td>
<td>NONE</td>
<td>NONE</td>
<td>NONE</td>
</tr>
<tr>
<td>Water for Injection</td>
<td>3.6%</td>
<td>7732-18-5</td>
<td>NONE</td>
<td>NONE</td>
<td>NONE</td>
</tr>
</tbody>
</table>

Cyclosporin is a sterile injectable liquid drug provided in a 5 mL vial.

Section III - HEALTH HAZARD DATA

Routes of Entry: Product is an immunosuppressive and may be absorbed via skin, inhalation, or ingestion. Product is intended for intradermal administration for the prevention of rejection following organ (kidney, liver and heart) transplantation.

Health Hazard (Acute & Chronic): Product affects the immune system, kidneys, liver, central nervous system, pancreas, and cardiovascular system. Product is a human carcinogen and may be a reproductive health hazard and mutagen.
Carcinogenicity: NTP? YES IARC Monographs? YES Sufficient Human Evidence Limited Animal Evidence Group 1

OSHA Regulated? NO

Signs & Symptoms of Exposure: Irritation to eyes, skin, and respiratory tract or possible allergic reaction. Kidney toxicity, bleeding, tender/swollen gums, increased hair growth, trembling hands, headache, leg cramps, nausea or vomiting, fever, chills, and the urge to urinate. Cyclosporin has been found excreted in human milk.

Medical Conditions Generally Aggravated by Exposure: Allergic reaction to Cyclosporin and/or Cremophor EL®

BVL Hazard Category: 4

Section IV - FIRST AID MEASURES

Eye Exposure: Flush eyes with large volumes of water for 15 or more minutes.
Skin Exposure: Wash skin with cool, soapy water.
Ingestion: If ingestion occurs, flush mouth out with water and seek medical attention immediately.
  If person is conscious, induce vomiting. Never induce vomiting on an unconscious person.
Inhalation: If difficulty breathing, administer oxygen. Seek attention of a physician immediately.
  If necessary, provide artificial respiration.
  Overdose should be treated symptomatically

Section V - FIRE AND EXPLOSION HAZARD DATA

Flash Point (Method Used): 80°F Closed-cup
Flammable Limits: Not Available LEL: Not Available UEL: Not Available
Extinguishing Media: Use a multi-purpose ABC fire extinguisher.
Special Fire Fighting Procedures: As with all fires, evacuate personnel to a safe area. Fire fighters should wear self-contained breathing apparatus to avoid inhalation of smoke.
Unusual Fire/Explosion Hazards: Ethyl alcohol is flammable. Keep this product away from ignition sources.

Section VI - ACCIDENTAL RELEASE INFORMATION

Release to Land: Since Cyclosporin is a flammable solution, remove all sources of ignition. Absorb Cyclosporin with activated charcoal or sorbent pads and dispose of according to local, state, and federal guidelines.
Release to Air: If aerosolized, reduce exposures by ventilating area; clean up spills immediately to prevent evaporation.
Release to Water: Refer to local water authority. Do not dispose of down the drain.

Section VII - PRECAUTIONS FOR SAFE HANDLING AND USE

Steps to be taken in case material is released or spilled: See Section VI above. Wear nitrile gloves and safety glasses. If vapors are generated, an appropriate air purifying respirator with an organic vapor cartridge and HEPA Filter (P100) must be worn. For larger spills, additional PPE and respiratory protection may be needed such as chemical protective coveralls, boots, double gloves (neoprene/nitrile), and self-contained breathing apparatus (SCBA).
**Waste Disposal Method:** Incinerate in an approved incinerator for flammable liquids according to local guidelines.

**Precautions to be taken in handling and storing:** Wash hands following use. No eating, drinking, or smoking while handling this product.

**Other Precautions:** Store below 86°F (30°C). Protect from light. Do not freeze.

---

### Section VIII - CONTROL MEASURES AND PERSONAL PROTECTIVE EQUIPMENT

**Respiratory Protection:** Under normal use, respirators are not required. If aerosols/vapors are generated, an air purifying respirator with organic vapor and HEPA cartridges (P100) may be necessary. For large spills, SCBA may be required. Personnel wearing respirators should be fit tested and approved for respirator use under the OSHA Respiratory Protection Standard 29 CFR 1910.134.

**Ventilation:** Handle in biological safety hood or a well-ventilated area.

**Protective Gloves:** Nitrile

**Eye Protection:** Safety glasses or splash goggles

**Other Protective Clothing or Equipment:** Lab coat

**Work/Hygienic Practices:** Wash hands following handling. No eating, drinking, or smoking while handling Cyclosporin.

---

### Section IX - PHYSICAL/CHEMICAL CHARACTERISTICS

**Physical State:** Liquid

**Appearance and Odor:** Clear with a mild odor

**Boiling Point:** Not Available

**Vapor Pressure:** Not Available

**Vapor Density:** Not Available

**Specific Gravity:** Not Available

**Melting Point:** Not Available

**Evaporation Rate:** Not Available

**Solubility in Water:** Not Available

**pH:** Not Available

---

### Section X - STABILITY AND REACTIVITY DATA

**Stability:** Stable

**Incompatibility (Materials to Avoid):** Strong bases and oxidizers

**Hazardous Decomposition or Byproducts:** Decomposition of this product may include potentially hazardous byproducts of combustion such as nitrogen oxides, carbon monoxide, and carbon dioxide.

**Hazardous Polymerization:** Will not occur

**Conditions to Avoid:** Do not store with strong bases and oxidizers

---

### Section XI - TOXICOLOGICAL INFORMATION

For Cyclosporin: RTECS # GZ4110000

- **LD<sub>50</sub>** rat, oral = 1480 mg/kg
- **LD<sub>50</sub>** mouse, intravenous = 148 mg/kg
- **LD<sub>50</sub>** mouse, oral = 2329 mg/kg
- **LD<sub>50</sub>** mouse, intramuscular = 145 mg/kg
- **LD<sub>50</sub>** rabbit, oral > 1000 mg/kg

Additional reproductive health and toxicity data is available from the National Institute for Occupational Safety and Health (NIOSH) Registry of Toxic Effects of Chemical Substances (RTECS).
Section XII - ENVIRONMENTAL IMPACT INFORMATION

Information is currently not available on the environmental impact of Cyclosporin. Handle in a manner to prevent spills or releases to the environment.

Section XIII - DISPOSAL INFORMATION

Dispose of by hazardous waste incineration at an approved/permitted facility according to local, state, and federal guidelines. Cyclosporin is flammable EPA code: D001
Follow local, state, and federal regulations.

Section XIV - TRANSPORTATION INFORMATION

Cyclosporin is a Hazardous Material per 49 CFR 172.101
Proper Shipping Name: Ethanol Solutions
Hazard class: 3 (Flammable liquid)
UN ID Number: UN 1170
Label and Placards: Flammable Liquid
Packing Group: II
Emergency Response Guide: 131
The chemicals in this product are not classified as DOT Marine Pollutants

Section XV - REGULATORY INFORMATION

SARA 313 listed?: NO
CERCLA listed?: NO
RCRA listed?: YES; D001 – Cyclosporin is a characteristic Flammable Waste D001.

Section XVI - OTHER DATA

1. Use of this product should be through or under the direction of a physician. This MSDS does not address the therapeutic use of this material.

2. Persons administering this drug to patients must be careful to avoid needle sticks to syringes and other sharps used in the administration. All needle sticks must be reported to your company management.

3. BVL Hazard Category Definitions (internal hazard ranking used by Ben Venue Laboratories):
   1 = Low Toxicity
   2 = Moderate Toxicity
   3 = Potent or Toxic
   4 = Highly Potent or Toxic
   5 = Extremely Potent or Toxic

4. OEL=Occupational Exposure Limit. An internal limit set by Ben Venue Laboratories for the recommended limit of employee exposure to airborne dusts or aerosols that should not be exceeded over an eight-hour time-weighted average.
5. Cyclosporin is considered a Hazardous Drug as described in the NIOSH Alert: Preventing Occupational Exposures to Antineoplastic and Other Hazardous Drugs in Health Care Settings. Employees who prepare or administer hazardous drugs or who work in areas where these drugs are used should follow specific handling guidelines in order to prevent exposure to these agents in the air or on work surfaces, clothing, or equipment.

6. **The Following Guidance Information is excerpted from the NIOSH Alert:**

Elements of a Hazardous Drug Handling Program include:

- Establishment and implementation of written policies and protocols to ensure the safe handling of oncolytic and/or potent drugs, including receipt of product.
- Training and education of employees on the recognition, evaluation and control of Hazardous Drugs
- Effective Planning and design of the workplace
- Use of best practice control measures and specialized equipment such as ventilated cabinets or isolators designed for worker protection
- Wearing recommended personal protective equipment
- An integrated health surveillance program that: includes the assessment and counseling of prospective employees before they commence any work involving oncolytic and/or potent drugs and related waste

7. **Published guidance on the handling and transport of cytotoxic drugs:**

NIOSH Alert – Preventing occupational exposures to antineoplastic and other hazardous drugs in health care settings
http://www.cdc.gov/niosh/docs/2004-165/

National Study Commission on Cytotoxic Exposure: Recommendation for handling Cytotoxic Agents:

This document is generated to distribute health, safety and environmental data. It is not a specification sheet and none of the displayed data should be construed as a specification. Information on this MSDS sheet was obtained from sources which we believe are reliable, and we believe that the information is complete and accurate. However, the information is provided without any warranty, express or implied, regarding its correctness. Some of the information presented and conclusions drawn are from sources other than direct test data of the substance. The conditions or methods of handling, storage, use and disposal of the product are beyond our control and may also be beyond our knowledge. It is the user’s responsibility to determine the suitability of any material for a specific purpose and to adopt such safety precautions as may be necessary. If the product is used as a component in another product, this MSDS information may not be applicable. For these reasons, we do not assume any responsibility and expressly disclaim liability for any loss, damage or expense arising out of or in any way connected with the handling, storage, use or disposal of this product.